Diagnostic accuracy of biochemical markers of fibrosis in black African patients with chronic hepatitis B

Mahassadi, Alassan Kouamé; Attia, Alain; Bathaix, Fulgence M. Yao; Agbe, N.; Doffou, Stanislas; Kissi, H.; Diomandé, Isidore; Calès, Paul; N’Dri-Yoman, Thérèse

doi:10.4236/health.2010.212210

Cited by 4 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…47 The AUROC of FIB-4 for significant fibrosis was 0.733. Mahassadi et al 48 had conducted a prospective cohort study to determine the diagnostic accuracy of APRI, AAR, AP and FIB-4 index for the prediction of significant fibrosis or cirrhosis in 117 patients with chronic hepatitis B and APRI and FIB-4 index ruled out significant fibrosis with high specificity of 84.7% and 86.1%, respectively. 48 Distinguishing severe stages (F3–F4) from low or moderate stages (F0–F2) of fibrosis with high FIB-4 scores (e.g.…”

Section: Discussionmentioning

confidence: 99%

Non-invasive serum fibrosis markers: A study in chronic hepatitis

Abdollahi¹,

Aliasghar²,

Ghojazadeh³

et al. 2017

Bioimpacts

View full text Add to dashboard Cite

Introduction: Chronic hepatitis is specified as inflammatory disease of the liver lasting for more than six months. Role of noninvasive fibrosis markers as prognostication factors of the presence or absence of significant fibrosis on liver biopsy of patients with chronic hepatitis is the aim of this study. Methods: Two hundred twenty-one patients with chronic hepatitis involved in the study between 2011 and 2013. Routine biochemical indices and serum fibrosis markers such as aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), AST to platelet ratio index (APRI) and Fibrosis 4 score (FIB-4) were evaluated, and the histological grade and stage of the liver biopsy specimens were scored according to the Ishak scoring system. Diagnostic accuracies of these markers for prediction of significant fibrosis were assessed by Receiver Operating Characteristic (ROC) curve analysis. Results: Contemporaneous laboratory indices for imputing AAR, APRI, and FIB-4 were identified with liver biopsies. From all, 135 males (61.1%) and 86 females (38.9%), with mean age of 39.6±14.4 were studied. Significant correlation between stages of fibrosis and FIB-4, APRI and AAR were detected, with a correlation coefficient higher than that of other markers in the patients with Hepatitis B (r = 0.46), C (r = 0.58) and autoimmune hepatitis (r = 0.28). FIB-4 (AUROC = 0.84) and APRI (AUROC = 0.78) were superior to AAR at distinguishing severe fibrosis from mild-to-moderate fibrosis and gave the highest diagnostic accuracy. Conclusion: Application of these markers was good at distinguishing significant fibrosis and decreased the need for staging liver biopsy specimens among patients with chronic hepatitis.

show abstract

Section: Discussionmentioning

confidence: 99%

Non-invasive serum fibrosis markers: A study in chronic hepatitis

Abdollahi¹,

Aliasghar²,

Ghojazadeh³

et al. 2017

Bioimpacts

View full text Add to dashboard Cite

show abstract

“…In Mahassadi's study [11] in Côte d'Ivoire, the average APRI score was 0.72 (IQR = 0.4-1.85). For Bonnard [12] in Burkina Faso, with an APRI score threshold value of 1.0, significant fibrosis could be correctly predicted with a sensitivity of 55% and a specificity of 50%.…”

Section: The Apri Scorementioning

confidence: 95%

“…If the reference examination remains hepatic biopsy, its invasiveness, high cost and inconsistent acceptability by patients, have motivated the development of new methods of evaluating fibrosis, called « non-invasive » tests. Many studies [4][5][6][7][8][9][10] including a few african studies [11,12] have led to proposing and then validating noninvasive tests capable of replacing liver biopsy to estimate the degree of fibrosis in patients with chronic hepatitis B and C viruses. In Togo, the prevalence of hepatits B virus (HBV) varies between 5% and 16.4% [13,14].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of hepatic fibrosis in patients with chronic hepatitis B virus by non-invasive methods: Aspartate-to-platelet ratio index, Fibrosis-4, fibrotest and fibroscan

Lawson-Ananissoh¹,

Bagny²,

Bouglouga³

et al. 2022

World J. Adv. Res. Rev.

View full text Add to dashboard Cite

Background: The process of hepatic fibrosis is common to the various etiologies of chronic liver disease such as viral hepatitis B. Objective: To evaluate hepatic fibrosis by non-invasive markers such as Aspartate-to-Platelet Ratio Index (APRI), fibrosis-4 (FIB-4), fibrotest and fibroscan. Patients and Method: This was a descriptive study during a period of 32 months. Included in our study were the records of outpatients, chronic carriers of hepatitis B virus without viral co-infection C, D or HIV, followed in the Gastroenterology unit of the Campus Teaching Hospital of Lome-Togo. Results: We retained 222 patients. Among the patients, 148 patients (66.67%) were classified in Phase 3 (inactive carrying). Only 10 patients (4.50%) had a APRI score indicating a fibrosis stage ≥ F4 (presence of cirrhosis). A FIB-4 score indicating the presence of cirrhosis was found in 12 patients (5.40%). The most represented stage at fibrotest was the F0 stage (45.45%). Cirrhosis was noted in 6.06% of cases at fibroscan. Patients with APRI score ≤ 2 (96.23%) had a FIB-4 score ≤ 3.25, (p = 0.0088). Conclusion: The evaluation of hepatic fibrosis during chronic hepatopathies is essential for patients care because it influences therapeutic decisions.

show abstract

“…The AUC of the AAR, AP and APRI index for predicting cirrhosis were respectively 0.555, 0.652 and 0.761. They concluded that these indices are good as noninvasive laboratory tests to predict cirrhosis in patients with HCV (Fujii et al, 2009 (Mahassadi et al, 2010). Kim determined the clinical performances of AAR, AP and APRI index for the prediction of liver fibrosis in chronic viral liver diseases in 225 patients with chronic viral liver diseases (180 with hepatitis B virus, 43 with hepatitis C virus, and 2 with hepatitis B+C virus) that underwent a liver biopsy procedure.…”

Section: Discussionmentioning

confidence: 99%